Genome Valley will be expanded by another 250 acres: KTR

HYDERABAD: Genome Valley, Asia's largest life sciences cluster in the city, will be expanded by another 250 acres, announced Telangana IT and Industries Minister KT Rama Rao (KTR).

KTR made the announcement during the ground breaking ceremony for Bharat Serums and Vaccines Limited (BSV) company’s new unit at Genome Valley on Thursday. On the occasion he said, "Telangana is the State with the most human resources in the country. We will provide all kinds of support to the BSV. We are currently undertaking phase-3 works in Genome Valley. It will be expanded by another 250 acres."

KTR added that Telangana has advantages which is unavailable elsewhere in the country.

"It is undeniable that the Telangana Government is working faster than anyone else in terms of industrialisation and employment generation. We do not care about the Central Government. There is always a 'panchayat' between between the BJP and the BRS. However, if they ask which is the number one State in Ease of Doing Business (EoDB), it is Telangana. The State is number one in terms of per capita income too. While the average per capita income of the country is Rs 1,49,000, the per capita income of Telangana is Rs 3,17,000."

Bharat Serums and Vaccine Limited BSV is one of the fastest growing biopharmaceutical companies in India. Headquartered in Mumbai, BSV is amongst the top 10 biotech companies in India.

Its new manufacturing facility in Genome Valley will cover an area of 10 acres and involve an investment of Rs 200 crore. It aims to provide long-term employment opportunities to the people of the Telangana State as well as upskilling of capabilities. With this manufacturing facility, BSV aims to significantly increase its capacity in producing injectables with the commissioning of the fill-finish formulation line in phase 1 and an additional multi-product line in phase 2 of the project. The manufacturing facility endeavours to produce world-class products that adhere to International Quality Systems while complying to the Indian regulatory norms of Schedule M as well as the Global regulatory requirements in the world. The facility will produce women health products, rabies vaccines, immunoglobulins, hormones, among others.